RIDDLE&CODE
31.5.2022 10:17:11 CEST | Business Wire | Press release
RIDDLE&CODE is now a member of the Catena-X Automotive Network e.V, an automotive association formed by leading industry players. Both Catena-X and RIDDLE&CODE aim to establish a decentralised data ecosystem through tokenization, tamper-proof identities, and digital twins of machines, vehicles and their components.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220525005104/en/
Catena-X is dedicated to developing an open, scalable industrial ecosystem that provides a data space and secure processes for all contributors across the automotive industry. The idea is to create a network where manufacturers, suppliers and all those involved in the value chain can participate in creating consistent means for data sharing and standardisation.
About the Catena-X Automotive Network
The Catena-X ecosystem consists of a consortium of 28 members from the automotive, business and scientific communities. It is funded by the German Ministry of Economic Affairs and Climate Action 0. The automotive industry launched a Public Association in 2021, which includes companies that actively want to shape the Catena-X ecosystem l. RIDDLE&CODE has become a member of the Association.
The strategic goal of Catena-X is to implement a standardised ecosystem across the automotive industry. This incentive was initiated by German companies in the automotive sector. It will then be adopted by the entirety of the European automobile industry and beyond.
While the Gaia-X infrastructure initiative aims to provide sovereign access to data via shared services for various industries, Catena-X specifically caters to the automotive industry. Data monetisation and implementation of token-based ecosystems are essential parts of the project. This has been done to drive these industry segments in the right direction of the environmental, social and governance (ESG) goals on different levels.
RIDDLE&CODE’s reasons to join
RIDDLE&CODE will contribute to the Catena-X network by bringing in its expertise in blockchain frameworks. This has been demonstrated through projects such as the European Blockchain Services Infrastructure PCP. RIDDLE&CODE, along with other partners, introduced a truly European architecture dubbed ZENBRIDGE. The project is supported by the European Commission.
Our ambition is to accelerate the move towards a transparent automotive ecosystem where data can be shared easily without facing obstacles from different proprietary infrastructures. Since its inception, RIDDLE&CODE has tackled these challenges.
"We are joining the association and partners to add our Trusted Car Wallet and Distributed Ledger Technology (DLT) software stack to the upcoming connected car data standards," said Minh Cao, Director of Mobility & Automotive at RIDDLE&CODE. "Our focus is to guarantee robust data directly from vehicles, providing trust and transparency to enable automation driven by AI and confidential edge computing."
"The objective is,” he continued, “to build a professional, standardised and modular toolchain for original equipment manufacturers (OEM) developers in the automotive ACES (Automated, Connected, Electric and Shared) and micromobility space that enables rapid prototyping of blockchain-based mobility solutions that leverage cryptographic techniques for data attestation and integration: tokenomics, decentralised data markets & data-rich vehicle networks. The RIDDLE&CODE toolchain will reduce complexity and simplify experimentation so that users can focus on building value-added business models whilst protecting manufacturers' intellectual property (IP)."
Catena-X includes major market shareholders such as BMW AG, Deutsche Telekom AG, Robert Bosch GmbH, Siemens AG, Mercedes-Benz AG and many more. Our membership will include exchanging ideas and technologies to further enrich this initiative.
About RIDDLE&CODE
RIDDLE&CODE is Europe’s leading company for blockchain interface solutions. The company develops hardware and software stacks that combine the security of smart cards with blockchain and the Internet of Things (IoT). Together with its tier-one clients and partners, which include Daimler Mobility, BMW, Wien Energie and leading Dutch crypto exchange LiteBit, RIDDLE&CODE brings new business models to the fintech, energy, mobility and materials industries.
More information: www.riddleandcode.com
About the Catena-X Automotive Network
Catena-X sees itself as a rapidly scalable, interoperable ecosystem in which all contributors in the automotive value chain can participate equally. The goal: to provide room for the creation, operation and collaborative use of end-to-end data chains along the entire automotive value chain. As of May 1st 2022, the Catena-X Automotive Network e.V. has 96 members who are active as providers and users in the automotive value chain and cover a wide range of company sizes.
More information: www.catena-x.net
View source version on businesswire.com: https://www.businesswire.com/news/home/20220525005104/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom